At the IGTP TODAY

News

- Research

IGTP researchers confirm the feasibility of immunotherapy in cells of the immune system of patients with type 1 diabetes

Researchers from the Immunology of Diabetes research group of the Germans Trias i Pujol Research Institute (IGTP) have confirmed, in human cells, that liposomes designed as immunotherapy for type 1 diabetes (T1D) are a valid strategy to arrest the autoimmune attack characteristic of this disease. They have done so in a preclinical study demonstrating the tolerogenic effect of these liposomes on cells of the immune system of patients with T1D. The results have been published in the journal Frontiers in Immunology.

- Campus Can Ruti, Research

Julia García Prado, new IGTP Scientific Director

Dr. García Prado, leader of the Viral Immune Evasion and Vacciones (VIRIEVAC) at the IrsiCaixa AIDS Research Institute will combine the new position with the leadership of her group, focused on the design of new strategies against HIV. Manel Puig, General Director of the IGTP, has presented the new organizational chart during the presentation of the Research Agenda 2018, together with the new challenges for the coming years.

- Research

The IGTP leads the biological and pathological studies in an international clinical trial focused on child and adolescent liver tumours

It is the first and largest international clinical trial ever in this type of patients. IGTP researchers coordinate what is going to be a unique collection in Europe of biological samples for this segment of patients, and will lead the posterior studies. Liver cancer in children is classified as a rare diseases and, in Spain, 15 cases are diagnoses every year.